KR102107812B1 - 인지기능 및 기억력 개선용 실크 유래 펩타이드의 제조방법 - Google Patents
인지기능 및 기억력 개선용 실크 유래 펩타이드의 제조방법 Download PDFInfo
- Publication number
- KR102107812B1 KR102107812B1 KR1020190141469A KR20190141469A KR102107812B1 KR 102107812 B1 KR102107812 B1 KR 102107812B1 KR 1020190141469 A KR1020190141469 A KR 1020190141469A KR 20190141469 A KR20190141469 A KR 20190141469A KR 102107812 B1 KR102107812 B1 KR 102107812B1
- Authority
- KR
- South Korea
- Prior art keywords
- silk
- derived peptide
- cognitive function
- memory
- enzyme
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 63
- 230000003920 cognitive function Effects 0.000 title claims description 29
- 238000002360 preparation method Methods 0.000 title description 5
- 108010022355 Fibroins Proteins 0.000 claims abstract description 42
- 238000004519 manufacturing process Methods 0.000 claims abstract description 26
- 102000004190 Enzymes Human genes 0.000 claims abstract description 23
- 108090000790 Enzymes Proteins 0.000 claims abstract description 23
- 229940088598 enzyme Drugs 0.000 claims abstract description 23
- 108091005804 Peptidases Proteins 0.000 claims abstract description 16
- 239000004365 Protease Substances 0.000 claims abstract description 15
- 102000035195 Peptidases Human genes 0.000 claims abstract description 12
- 108090000526 Papain Proteins 0.000 claims abstract description 11
- 229940055729 papain Drugs 0.000 claims abstract description 11
- 235000019834 papain Nutrition 0.000 claims abstract description 11
- 239000006166 lysate Substances 0.000 claims abstract description 5
- 230000000694 effects Effects 0.000 claims description 33
- 238000010438 heat treatment Methods 0.000 claims description 19
- 230000003301 hydrolyzing effect Effects 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 3
- 238000004090 dissolution Methods 0.000 claims description 2
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 claims description 2
- 239000000203 mixture Substances 0.000 abstract description 12
- 230000007062 hydrolysis Effects 0.000 abstract description 8
- 238000006460 hydrolysis reaction Methods 0.000 abstract description 8
- 108010032088 Calpain Proteins 0.000 abstract description 4
- 102000007590 Calpain Human genes 0.000 abstract description 4
- -1 Protamex Proteins 0.000 abstract description 4
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 abstract description 4
- 235000019419 proteases Nutrition 0.000 abstract description 4
- 108010009355 microbial metalloproteinases Proteins 0.000 abstract description 3
- 238000000034 method Methods 0.000 description 29
- 108010013296 Sericins Proteins 0.000 description 23
- 150000001413 amino acids Chemical class 0.000 description 23
- 235000001014 amino acid Nutrition 0.000 description 22
- 241001465754 Metazoa Species 0.000 description 12
- 102000004196 processed proteins & peptides Human genes 0.000 description 12
- 108090000623 proteins and genes Proteins 0.000 description 12
- 235000018102 proteins Nutrition 0.000 description 11
- 102000004169 proteins and genes Human genes 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 230000006872 improvement Effects 0.000 description 10
- 206010012289 Dementia Diseases 0.000 description 9
- 238000010521 absorption reaction Methods 0.000 description 9
- 238000010171 animal model Methods 0.000 description 8
- 210000004556 brain Anatomy 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 208000028867 ischemia Diseases 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- 239000008213 purified water Substances 0.000 description 8
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
- 206010008118 cerebral infarction Diseases 0.000 description 6
- 208000026106 cerebrovascular disease Diseases 0.000 description 6
- 208000010877 cognitive disease Diseases 0.000 description 6
- 230000006698 induction Effects 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 102000004157 Hydrolases Human genes 0.000 description 5
- 108090000604 Hydrolases Proteins 0.000 description 5
- 102000007530 Neurofibromin 1 Human genes 0.000 description 5
- 108010085793 Neurofibromin 1 Proteins 0.000 description 5
- 238000000354 decomposition reaction Methods 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- 201000011240 Frontotemporal dementia Diseases 0.000 description 4
- 238000005903 acid hydrolysis reaction Methods 0.000 description 4
- 239000000654 additive Substances 0.000 description 4
- 230000000996 additive effect Effects 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000000302 ischemic effect Effects 0.000 description 4
- 230000006386 memory function Effects 0.000 description 4
- 206010061216 Infarction Diseases 0.000 description 3
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
- 208000012902 Nervous system disease Diseases 0.000 description 3
- 208000025966 Neurological disease Diseases 0.000 description 3
- 239000004677 Nylon Substances 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 235000004279 alanine Nutrition 0.000 description 3
- 210000001367 artery Anatomy 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 210000000269 carotid artery external Anatomy 0.000 description 3
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 108091005899 fibrous proteins Proteins 0.000 description 3
- 102000034240 fibrous proteins Human genes 0.000 description 3
- 230000007574 infarction Effects 0.000 description 3
- 229920001778 nylon Polymers 0.000 description 3
- 238000005192 partition Methods 0.000 description 3
- 230000001766 physiological effect Effects 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 208000030507 AIDS Diseases 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- 241000255789 Bombyx mori Species 0.000 description 2
- 206010012218 Delirium Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 125000000998 L-alanino group Chemical group [H]N([*])[C@](C([H])([H])[H])([H])C(=O)O[H] 0.000 description 2
- 208000009829 Lewy Body Disease Diseases 0.000 description 2
- 201000002832 Lewy body dementia Diseases 0.000 description 2
- 208000000609 Pick Disease of the Brain Diseases 0.000 description 2
- 208000024571 Pick disease Diseases 0.000 description 2
- 108010009736 Protein Hydrolysates Proteins 0.000 description 2
- 201000004810 Vascular dementia Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000008484 agonism Effects 0.000 description 2
- 235000008206 alpha-amino acids Nutrition 0.000 description 2
- 201000007201 aphasia Diseases 0.000 description 2
- 210000001715 carotid artery Anatomy 0.000 description 2
- 210000004004 carotid artery internal Anatomy 0.000 description 2
- 230000001149 cognitive effect Effects 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 230000007071 enzymatic hydrolysis Effects 0.000 description 2
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 2
- 235000013376 functional food Nutrition 0.000 description 2
- 201000003723 learning disability Diseases 0.000 description 2
- 206010027175 memory impairment Diseases 0.000 description 2
- 230000006993 memory improvement Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 208000027061 mild cognitive impairment Diseases 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 238000012549 training Methods 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- PKDBCJSWQUOKDO-UHFFFAOYSA-M 2,3,5-triphenyltetrazolium chloride Chemical compound [Cl-].C1=CC=CC=C1C(N=[N+]1C=2C=CC=CC=2)=NN1C1=CC=CC=C1 PKDBCJSWQUOKDO-UHFFFAOYSA-M 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 235000019750 Crude protein Nutrition 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000032382 Ischaemic stroke Diseases 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000001370 alpha-amino acid derivatives Chemical class 0.000 description 1
- 150000001371 alpha-amino acids Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 210000001168 carotid artery common Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000001627 cerebral artery Anatomy 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003257 excitatory amino acid Substances 0.000 description 1
- 230000002461 excitatory amino acid Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 235000020510 functional beverage Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000008897 memory decline Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 208000028173 post-traumatic stress disease Diseases 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000007065 protein hydrolysis Effects 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 230000010410 reperfusion Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- YXVCLPJQTZXJLH-UHFFFAOYSA-N thiamine(1+) diphosphate chloride Chemical compound [Cl-].CC1=C(CCOP(O)(=O)OP(O)(O)=O)SC=[N+]1CC1=CN=C(C)N=C1N YXVCLPJQTZXJLH-UHFFFAOYSA-N 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
- C07K14/43563—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects
- C07K14/43586—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects from silkworms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Psychiatry (AREA)
- Insects & Arthropods (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Toxicology (AREA)
- General Chemical & Material Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
도 2는 본 발명의 일 실시예에 따라 제조된 실크 펩타이드에 관한 인지기억평가실험 결과에 관한 것이다.
도 3은 본 발명의 일 실시예에 따라 제조된 실크 펩타이드의 허혈에 의한 뇌경색 부위에 대한 효과실험 결과에 대한 것이다.
| T1 | T2 | T3 | T4 | T5 | T6 | T7 | T8 | T9 | T10 | T11 | |
| 플라보자임 | 100 | - | - | - | - | - | - | - | - | - | - |
| 프로타맥스 | - | 100 | - | - | - | - | - | - | - | - | - |
| 파파인 | - | - | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| 징지바인 | - | - | - | 5 | 10 | 30 | 50 | 60 | 30 | 30 | 30 |
| 칼파인 | - | - | - | 5 | 10 | 20 | 30 | 40 | 20 | 20 | 20 |
| 우마미자임 | - | - | - | - | - | - | - | - | 0.5 | 10 | 25 |
| NF1 | NF2 | NF3 | NF4 | NF5 | NF6 | NF7 | NF8 | NF9 | NF10 | NF11 | |
| 처리효소 | T1 | T2 | T3 | T4 | T5 | T6 | T7 | T8 | T9 | T10 | T11 |
Claims (6)
- 실크 피브로인을 용해시키는 용해 단계;
상기 실크 피브로인 용해물에 파파인을 포함하고, 파파인 100 중량부에 대하여 징지바인 10 내지 50 중량부, 칼파인 5 내지 30 중량부를 혼합시킨 혼합 효소를 단백질 가수분해 효소로 처리하여 가수분해하는 단계; 및
단백질 가수분해 효소를 제거하는 효소 제거단계를 포함하는
인지기능 및 기억력 개선용 실크 유래 펩타이드의 제조방법. - 제 1항에 있어서,
상기 단백질 가수분해 효소는 우마미자임(Umamizyme)을 더 포함하는 것인
인지기능 및 기억력 개선용 실크 유래 펩타이드의 제조방법. - 제 1항에 있어서,
상기 효소 제거단계는 열처리 하여 효소의 활성을 제거하는 것인
인지기능 및 기억력 개선용 실크 유래 펩타이드의 제조방법. - 삭제
- 삭제
- 삭제
Priority Applications (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020190141469A KR102107812B1 (ko) | 2019-11-07 | 2019-11-07 | 인지기능 및 기억력 개선용 실크 유래 펩타이드의 제조방법 |
| AU2020368789A AU2020368789B2 (en) | 2019-10-16 | 2020-08-28 | Peptide for improving memory and preventing or alleviating cognitive impairment, composition containing same and preparation method therefor |
| CN202080058603.0A CN114269768A (zh) | 2019-10-16 | 2020-08-28 | 用于改善记忆力和预防或改善认知功能障碍的肽及包含该肽的组合物、及其制备方法 |
| PCT/KR2020/011579 WO2021075707A1 (ko) | 2019-10-16 | 2020-08-28 | 기억력 개선 및 인지기능장애 예방 또는 개선용 펩타이드 및 이를 포함하는 조성물, 그리고 그 제조방법 |
| CA3151414A CA3151414A1 (en) | 2019-10-16 | 2020-08-28 | Peptide for improving memory and preventing or alleviating cognitive impairment, composition containing same and preparation method therefor |
| US17/023,248 US12264204B2 (en) | 2019-10-16 | 2020-09-16 | Peptide for improving memory and preventing or alleviating cognitive dysfunction, composition comprising the same, and method for producing the same |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020190141469A KR102107812B1 (ko) | 2019-11-07 | 2019-11-07 | 인지기능 및 기억력 개선용 실크 유래 펩타이드의 제조방법 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR102107812B1 true KR102107812B1 (ko) | 2020-05-07 |
Family
ID=70733154
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020190141469A Active KR102107812B1 (ko) | 2019-10-16 | 2019-11-07 | 인지기능 및 기억력 개선용 실크 유래 펩타이드의 제조방법 |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR102107812B1 (ko) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021075707A1 (ko) * | 2019-10-16 | 2021-04-22 | 주식회사 네이처센스 | 기억력 개선 및 인지기능장애 예방 또는 개선용 펩타이드 및 이를 포함하는 조성물, 그리고 그 제조방법 |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20010079286A (ko) | 2001-07-03 | 2001-08-22 | 주육현 | 누에고치를 이용한 기능성 실크아미노산·펩타이드 소재의제조 방법 중 염산가수분해법에 의한 제조방법 |
| KR20010105931A (ko) | 2000-05-19 | 2001-11-29 | 권혁윤 | 실크 펩타이드를 제조하는 방법 |
| KR20050040124A (ko) * | 2005-03-31 | 2005-05-03 | 주식회사 바이오그랜드 | 뇌신경질환의 예방 또는 치료용 식품 조성물 |
| KR20050052666A (ko) * | 2002-10-10 | 2005-06-03 | 다이버사 코포레이션 | 프로테아제, 이를 암호화하는 핵산, 및 이를 제조하고사용하는 방법 |
| WO2011104630A1 (en) * | 2010-02-26 | 2011-09-01 | Council Of Scientific & Industrial Research | Enzymes from conidiobolus brefeldianus and process for preparation thereof |
| KR101931363B1 (ko) * | 2017-12-26 | 2018-12-20 | 주식회사 실크로 | 친환경적인 누에고치 유래 펩타이드의 제조방법 및 이로부터 제조된 누에고치 유래 펩타이드 |
| WO2019094700A1 (en) * | 2017-11-10 | 2019-05-16 | Cocoon Biotech Inc. | Silk-based products and methods of use |
-
2019
- 2019-11-07 KR KR1020190141469A patent/KR102107812B1/ko active Active
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20010105931A (ko) | 2000-05-19 | 2001-11-29 | 권혁윤 | 실크 펩타이드를 제조하는 방법 |
| KR20010079286A (ko) | 2001-07-03 | 2001-08-22 | 주육현 | 누에고치를 이용한 기능성 실크아미노산·펩타이드 소재의제조 방법 중 염산가수분해법에 의한 제조방법 |
| KR20050052666A (ko) * | 2002-10-10 | 2005-06-03 | 다이버사 코포레이션 | 프로테아제, 이를 암호화하는 핵산, 및 이를 제조하고사용하는 방법 |
| KR20050040124A (ko) * | 2005-03-31 | 2005-05-03 | 주식회사 바이오그랜드 | 뇌신경질환의 예방 또는 치료용 식품 조성물 |
| WO2011104630A1 (en) * | 2010-02-26 | 2011-09-01 | Council Of Scientific & Industrial Research | Enzymes from conidiobolus brefeldianus and process for preparation thereof |
| WO2019094700A1 (en) * | 2017-11-10 | 2019-05-16 | Cocoon Biotech Inc. | Silk-based products and methods of use |
| KR101931363B1 (ko) * | 2017-12-26 | 2018-12-20 | 주식회사 실크로 | 친환경적인 누에고치 유래 펩타이드의 제조방법 및 이로부터 제조된 누에고치 유래 펩타이드 |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021075707A1 (ko) * | 2019-10-16 | 2021-04-22 | 주식회사 네이처센스 | 기억력 개선 및 인지기능장애 예방 또는 개선용 펩타이드 및 이를 포함하는 조성물, 그리고 그 제조방법 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Miguel et al. | Antihypertensive peptides derived from egg proteins | |
| DE60028575T2 (de) | Peptiden reich an Cystein und/oder Glycin | |
| RU2219925C2 (ru) | Аминокислотные композиции и их применение при иммунодепрессии | |
| KR102107812B1 (ko) | 인지기능 및 기억력 개선용 실크 유래 펩타이드의 제조방법 | |
| KR102107821B1 (ko) | 생산성이 향상된 실크 피브로인 가수분해물 제조방법 및 이를 이용하여 제조된 실크 피브로인 가수분해물 | |
| KR102107809B1 (ko) | 실크 유래 펩타이드의 제조방법 | |
| KR102107813B1 (ko) | 인지기능 및 기억력 개선용 실크 유래 기능성 단백질의 제조방법 | |
| KR102107820B1 (ko) | 생산성이 향상된 실크 피브로인 가수분해물 제조방법 및 이를 이용하여 제조된 실크 피브로인 가수분해물 | |
| KR102107814B1 (ko) | 기억력 개선, 인지기능장애 예방 및 개선을 위한 실크 피브로인 유래 펩타이드의 제조방법 | |
| US12264204B2 (en) | Peptide for improving memory and preventing or alleviating cognitive dysfunction, composition comprising the same, and method for producing the same | |
| KR102107815B1 (ko) | 기억력 개선용 실크 유래 펩타이드 조성물 | |
| KR102107817B1 (ko) | 인지장애 및 기억력 개선용 단백질 조성물 | |
| KR102107819B1 (ko) | 생산성이 향상된 인지기능 및 기억력 개선용 실크 피브로인 가수분해물 제조방법 및 이를 이용하여 제조된 실크 피브로인 가수분해물 | |
| KR102107816B1 (ko) | 인지기능 및 기억력 개선용 실크 유래 펩타이드 조성물 | |
| KR102153103B1 (ko) | 실크 피브로인 유래 펩타이드의 제조방법 및 이를 이용한 기억력 및 인지기능 개선용 조성물 | |
| KR102239629B1 (ko) | 실크 펩타이드의 제조방법 및 이를 이용하여 제조된 기억력 및 인지능력 개선용 조성물 | |
| US7589062B2 (en) | Two synthetic peptides for treatment and prevention of cancers | |
| KR20220166609A (ko) | 실크펩타이드를 유효성분으로 하는 뇌신경질환 예방 및 치료용 조성물 | |
| KR102107824B1 (ko) | 식품용 실크 피브로인의 가용화 조성물 및 실크 펩타이드 제조용 가용화 된 실크 피브로인 | |
| KR102107818B1 (ko) | 기억력 및 인지기능 개선용 실크 펩타이드를 제조하기 위한 실크 가용화 방법 및 그 가수분해물의 제조방법 | |
| KR102107835B1 (ko) | 실크 피브로인 가용화 방법 및 그 가수분해물의 제조방법 | |
| KR102107825B1 (ko) | 실크 피브로인 가용화 방법 및 그 가수분해물의 제조방법 | |
| RU2128448C1 (ru) | Способ переработки боенской крови | |
| KR102107822B1 (ko) | 실크 피브로인 가용화 전처리 조성물 및 이를 이용하여 가용화 된 실크 피브로인 | |
| KR102107823B1 (ko) | 실크 가용화용 조성물 및 이를 이용하여 가용화 된 실크 단백질 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 20191107 |
|
| PA0201 | Request for examination | ||
| PA0302 | Request for accelerated examination |
Patent event date: 20191108 Patent event code: PA03022R01D Comment text: Request for Accelerated Examination Patent event date: 20191107 Patent event code: PA03021R01I Comment text: Patent Application |
|
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20200107 Patent event code: PE09021S01D |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20200310 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20200428 Patent event code: PR07011E01D |
|
| PR1002 | Payment of registration fee |
Payment date: 20200428 End annual number: 3 Start annual number: 1 |
|
| PG1601 | Publication of registration | ||
| PR1001 | Payment of annual fee |
Payment date: 20240429 Start annual number: 5 End annual number: 5 |
|
| PR1001 | Payment of annual fee |
Payment date: 20250428 Start annual number: 6 End annual number: 6 |